Jorgensen J H
Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7750.
Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):245-9. doi: 10.1016/0732-8893(93)90117-p.
Each clinical microbiology laboratory must establish its own standard battery of antimicrobial agents to be tested routinely on clinical isolates of various organism groups. Some choices are based upon the intrinsic activities of antimicrobial agents for a particular group of organisms, for example, agents primarily active against either Gram-positive or Gram-negative bacteria. For final selection of limited batteries of agents for routine testing, however, it is necessary to use additional criteria based upon physician prescribing patterns and the availability of antimicrobial agents in a particular institution. A fundamental principle in the selection process should be routine testing and reporting of those antimicrobial agents that physicians actually use, that is, the institution's formulary agents. Testing of the most appropriate drugs for an institution may be complicated by lack of availability of some antimicrobial agents among the standard panels offered by automated instrument or commercial test system manufacturers. The laboratory should develop its final test batteries in consultation with the infectious disease and pharmacy services and the pharmacy and therapeutics and infection-control committees of the medical staff. These choices should not be made based upon the most convenient selection of drugs from the laboratory's perspective or based upon pharmaceutical industry promotional efforts.
每个临床微生物实验室都必须建立自己的标准抗菌药物组合，以便对各类生物体的临床分离株进行常规检测。某些选择是基于抗菌药物对特定生物体组的内在活性，例如，主要对革兰氏阳性或革兰氏阴性细菌有活性的药物。然而，对于常规检测的有限药物组合的最终选择，有必要根据医生的处方模式和特定机构中抗菌药物的可获得性使用其他标准。选择过程中的一个基本原则应该是对医生实际使用的那些抗菌药物进行常规检测和报告，即该机构的处方药物。由于自动化仪器或商业测试系统制造商提供的标准检测板中缺乏某些抗菌药物，对机构最合适药物的检测可能会变得复杂。实验室应与传染病和药学服务部门以及医务人员的药学与治疗学和感染控制委员会协商制定其最终检测药物组合。这些选择不应基于从实验室角度最方便的药物选择，也不应基于制药行业的促销努力。
